^
    5d
    A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, Calibr, a division of Scripps Research | Trial completion date: Nov 2028 --> Jun 2026 | Trial primary completion date: Nov 2028 --> Jun 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    21d
    DUSP6 ablation restores CAR T-cell fitness impaired by tumor CD58 loss through invigoration of AP-1 signaling. (PubMed, Signal Transduct Target Ther)
    Here, we revealed that AP-1-mediated activation was attenuated in CAR T cells impaired by tumor CD58 loss, driving a decrease in mitochondrial biogenesis, metabolic kinetic impairment, mitochondrial membrane potential loss and ROS accumulation...Our findings repositioned CD58 not merely as an immune synapse component but also a metabolic checkpoint in CAR T-cell biology, the loss of which triggers AP-1-dependent mitochondrial derangement and creates a permissive landscape for intrinsic apoptosis, which can be ameliorated by ablation of the inhibitory phosphatase DUSP6. Crucially, DUSP6 ablation represents a promising engineering target to potentiate CAR T-cell efficacy in broader applications.
    Journal
    |
    CD58 (CD58 Molecule) • DUSP6 (Dual specificity phosphatase 6)
    29d
    Exploratory Clinical Study on the Safety of STR-P004 (clinicaltrials.gov)
    P=N/A, N=39, Recruiting, Beijing GoBroad Hospital | Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2026 --> Aug 2026
    Enrollment open • Trial primary completion date
    1m
    LIBERATE: Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, Quell Therapeutics Limited | Recruiting --> Active, not recruiting | Trial completion date: Mar 2040 --> Sep 2040 | Trial primary completion date: Sep 2025 --> Feb 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    2ms
    Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Sonoma Biotherapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    2ms
    Preliminary Exploratory Clinical Study of TC-D101 in the Treatment of DLL3-Positive Relapsed/Refractory Primary Small-Cell Lung Cancer (ChiCTR2500112639)
    P=N/A, N=8, Not yet recruiting, Eastern Theater Command General Hospital of the Chinese People's Liberation Army (Jinling Hospital, Affiliated to Nanjing University Medical School);
    New trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    2ms
    Preliminary Exploratory Clinical Study of TC-G203 for the Treatment of GPC3-Positive Recurrent/Metastatic Solid Tumors (ChiCTR2500112333)
    P=N/A, N=14, Not yet recruiting, Beijing Gaobo Hospital; Beijing Gaobo Hospital
    New trial
    |
    GPC3 (Glypican 3)
    2ms
    An early clinical study to evaluate the safety and clinical efficacy of STR-P004 in subjects with relapsed/refractory CD19-positive acute lymphoblastic leukemia (ChiCTR2500111445)
    P=N/A, N=30, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New trial
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    2ms
    A Phase 1, First-in-Human, Investigator-Initiated, Open-label Study to Assess the Safety, Feasibility, Cytokinetics, and Preliminary Antitumor Activity of GC511B in Adult Subjects with DLL3+ Relapsed/Refractory Small Cell Lung Cancer (ChiCTR2500111823)
    P1, N=100, Not yet recruiting, CancerCancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences Hospital
    New P1 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    2ms
    To Evaluate the Safety and Tolerability of STR-P004 for the Treatment of Immune-mediated Kidney Diseases (clinicaltrials.gov)
    P=N/A, N=9, Not yet recruiting, Starna Therapeutics
    New trial
    |
    CD19 positive
    3ms
    TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Beijing GoBroad Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GPC3 (Glypican 3)
    |
    cyclophosphamide • fludarabine IV
    3ms
    Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC (clinicaltrials.gov)
    P1, N=12, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P1 trial